The approval was based on a placebo-controlled, multi-center trial called Breast cancer trials of OraL EveROlimus-2, which evaluated 724 postmenopausal women with advanced HR+ breast cancer with recurrence
The trial evaluated the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets for patients with unresectable liver cancer. The addition of Tarceva
As per the agreement, each outstanding share of Callisto common stock will be exchanged for 0.17 shares of Synergy common stock and the 22,295,000 shares of Synergy held
Kyprolis is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent,
The antipsychotic agent exhibits pharmacological properties, potent anxiolytic effect, sedative/hypotonic effect and relief from myotonia. The drug is indicated for psychosomatic disease, neurosis, low back pain, cervical spondylosis
The study showed a significantly higher rate of survival among NHPs treated with AVI-7288 compared to the placebo-treated group when treatment was administered up to 96-hours post infection.
The 28 healthy adult volunteers in the study were co-administered with pitavastatin and darunavir/ritonavir over a 16-day period, The study showed no clinically significant change in blood levels
Crizotinib, an oral ALK inhibitor, blocks signaling in a number of cell pathways that are believed to be critical for the growth and survival of tumor cells, by
Adva-27a is an anti-cancer compound which has proven effective at killing multidrug resistant breast cancer cells (MCF-7/MDR) and small-cell lung cancer cells (H69AR). Sunshine president and CEO Steve
The launch was based on the completion of clinical evaluation of EasyCell analyzer at Boston Children’s Hospital, which confirmed the instrument’s efficacy in the hematology laboratory environment. Boston
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.